NEWS: 公告在东京证券交易所JASDAQ标准市场新上市

表纸
市场调查报告书

全球眼睑炎治疗药市场(2021年-2025年)

Global Blepharitis Drugs Market 2021-2025

出版商 TechNavio (Infiniti Research Ltd.) 商品编码 987825
出版日期 内容资讯 英文 120 Pages
订单完成后即时交付
价格
全球眼睑炎治疗药市场(2021年-2025年) Global Blepharitis Drugs Market 2021-2025
出版日期: 2021年02月08日内容资讯: 英文 120 Pages
简介

全球眼睑炎治疗药的市场规模在2021年~2025年间,预测将成长到3亿5,538万美元,这个期间中的年复合成长率预测将为5%。市场成长的主要因素有眼睑炎的组合药和高风险因子的使用增加。

本报告提供眼睑炎治疗药市场调查,提供市场概要,市场成长要素及阻碍因素分析,各产品·各地区的市场规模的变化与预测,供应商分析,市场机会等全面性资讯。

目录

摘要整理

市场形势

市场规模

  • 市场定义
  • 市场区隔分析
  • 市场规模2020
  • 市场预测:从2020年~2025年的预测

波特的五力分析

各产品的市场区隔

  • 市场·市场区隔
  • 各产品比较
  • 类固醇-市场规模与预测(2020年~2025年)
  • 抗生素-市场规模与预测(2020年~2025年)
  • 各产品的市场机会

客户形势

各地区形势

  • 各地区市场区隔
  • 各地区比较
  • 北美-市场规模与预测(2020年~2025年)
  • 欧洲-市场规模与预测(2020年~2025年)
  • 亚洲-市场规模与预测(2020年~2025年)
  • 其他地区-市场规模与预测(2020年~2025年)
  • 主要的主要国家
  • 地区的市场机会
  • 市场推动因素
  • 市场课题
  • 市场趋势

业者情势

  • 竞争模式
  • 业者情势
  • 创造性破坏状况

供应商分析

  • 交易厂商
  • 供应商的市场定位
  • AbbVie Inc.
  • Akorn Inc.
  • Alembic Pharmaceuticals Ltd.
  • Bausch Health Companies Inc.
  • Bayer AG
  • GlaxoSmithKline Plc
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Santen Pharmaceutical Co. Ltd.

附录

目录
Product Code: IRTNTR70118

Technavio has been monitoring the blepharitis drugs market and it is poised to grow by $ 355.38 mn during 2021-2025 progressing at a CAGR of 5% during the forecast period. Our report on blepharitis drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing use of combination drugs and high-risk factors for blepharitis. In addition, increasing use of combination drugs is anticipated to boost the growth of the market as well.

The blepharitis drugs market analysis includes product segment and geographical landscapes.

Technavio's blepharitis drugs market is segmented as below:

By Product

  • Steroids
  • Antibiotics

By Geographical Landscapes

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the growing awareness about eye diseases as one of the prime reasons driving the blepharitis drugs market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on blepharitis drugs market covers the following areas:

  • Blepharitis drugs market sizing
  • Blepharitis drugs market forecast
  • Blepharitis drugs market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading blepharitis drugs market vendors that include AbbVie Inc., Akorn Inc., Alembic Pharmaceuticals Ltd., Bausch Health Companies Inc., Bayer AG, GlaxoSmithKline Plc, Novartis AG, Pfizer Inc., Sanofi, and Santen Pharmaceutical Co. Ltd.. Also, the blepharitis drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020 - 2025

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Product

  • Market segments
  • Comparison by Product
  • Steroids - Market size and forecast 2020-2025
  • Antibiotics - Market size and forecast 2020-2025
  • Market opportunity by Product

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2020-2025
  • Europe - Market size and forecast 2020-2025
  • Asia - Market size and forecast 2020-2025
  • ROW - Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Competitive scenario
  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • AbbVie Inc.
  • Akorn Inc.
  • Alembic Pharmaceuticals Ltd.
  • Bausch Health Companies Inc.
  • Bayer AG
  • GlaxoSmithKline Plc
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Santen Pharmaceutical Co. Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2020 - 2025 ($ million)
  • 13: Global market: Year-over-year growth 2020 - 2025 (%)
  • 14: Five forces analysis 2020 & 2025
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2020
  • 21: Product - Market share 2020-2025 (%)
  • 22: Comparison by Product
  • 23: Steroids - Market size and forecast 2020-2025 ($ million)
  • 24: Steroids - Year-over-year growth 2020-2025 (%)
  • 25: Antibiotics - Market size and forecast 2020-2025 ($ million)
  • 26: Antibiotics - Year-over-year growth 2020-2025 (%)
  • 27: Market opportunity by Product
  • 28: Customer landscape
  • 29: Market share by geography 2020-2025 (%)
  • 30: Geographic comparison
  • 31: North America - Market size and forecast 2020-2025 ($ million)
  • 32: North America - Year-over-year growth 2020-2025 (%)
  • 33: Europe - Market size and forecast 2020-2025 ($ million)
  • 34: Europe - Year-over-year growth 2020-2025 (%)
  • 35: Asia - Market size and forecast 2020-2025 ($ million)
  • 36: Asia - Year-over-year growth 2020-2025 (%)
  • 37: ROW - Market size and forecast 2020-2025 ($ million)
  • 38: ROW - Year-over-year growth 2020-2025 (%)
  • 39: Key leading countries
  • 40: Market opportunity by geography ($ million)
  • 41: Impact of drivers and challenges
  • 42: Vendor landscape
  • 43: Landscape disruption
  • 44: Industry risks
  • 45: Vendors covered
  • 46: Market positioning of vendors
  • 47: AbbVie Inc. - Overview
  • 48: AbbVie Inc. - Business segments
  • 49: AbbVie Inc. - Key offerings
  • 50: AbbVie Inc. - Key customers
  • 51: AbbVie Inc. - Segment focus
  • 52: Akorn Inc. - Overview
  • 53: Akorn Inc. - Product and service
  • 54: Akorn Inc. - Key offerings
  • 55: Akorn Inc. - Key customers
  • 56: Akorn Inc. - Segment focus
  • 57: Alembic Pharmaceuticals Ltd. - Overview
  • 58: Alembic Pharmaceuticals Ltd. - Product and service
  • 59: Alembic Pharmaceuticals Ltd. - Key offerings
  • 60: Alembic Pharmaceuticals Ltd. - Key customers
  • 61: Alembic Pharmaceuticals Ltd. - Segment focus
  • 62: Bausch Health Companies Inc. - Overview
  • 63: Bausch Health Companies Inc. - Business segments
  • 64: Bausch Health Companies Inc. - Key offerings
  • 65: Bausch Health Companies Inc. - Key customers
  • 66: Bausch Health Companies Inc. - Segment focus
  • 67: Bayer AG - Overview
  • 68: Bayer AG - Business segments
  • 69: Bayer AG - Key offerings
  • 70: Bayer AG - Key customers
  • 71: Bayer AG - Segment focus
  • 72: GlaxoSmithKline Plc - Overview
  • 73: GlaxoSmithKline Plc - Business segments
  • 74: GlaxoSmithKline Plc - Key offerings
  • 75: GlaxoSmithKline Plc - Key customers
  • 76: GlaxoSmithKline Plc - Segment focus
  • 77: Novartis AG - Overview
  • 78: Novartis AG - Business segments
  • 79: Novartis AG - Key offerings
  • 80: Novartis AG - Key customers
  • 81: Novartis AG - Segment focus
  • 82: Pfizer Inc. - Overview
  • 83: Pfizer Inc. - Business segments
  • 84: Pfizer Inc. - Key offerings
  • 85: Pfizer Inc. - Key customers
  • 86: Pfizer Inc. - Segment focus
  • 87: Sanofi - Overview
  • 88: Sanofi - Business segments
  • 89: Sanofi - Key offerings
  • 90: Sanofi - Key customers
  • 91: Sanofi - Segment focus
  • 92: Santen Pharmaceutical Co. Ltd. - Overview
  • 93: Santen Pharmaceutical Co. Ltd. - Business segments
  • 94: Santen Pharmaceutical Co. Ltd. - Key offerings
  • 95: Santen Pharmaceutical Co. Ltd. - Key customers
  • 96: Santen Pharmaceutical Co. Ltd. - Segment focus
  • 97: Currency conversion rates for US$
  • 98: Research Methodology
  • 99: Validation techniques employed for market sizing
  • 100: Information sources
  • 101: List of abbreviations